We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants Comments on Program for Longer New Drug Reviews
FDA Wants Comments on Program for Longer New Drug Reviews
July 25, 2012
The FDA is seeking drugmaker comment on an upcoming independent assessment of its new lengthened review program under the newly reauthorized Prescription Drug User Fee Act (PDUFA).